Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Surgery, Democritus University of Thrace Medical School, Alexandroupoli, Greece.
J Am Coll Surg. 2018 May;226(5):933-938. doi: 10.1016/j.jamcollsurg.2018.01.007. Epub 2018 Mar 2.
Approximately 10% of patients with primary hyperparathyroidism (PHPT) have hereditary disease. Hereditary PHPT may be syndromic (MEN1, 2, and 4 and hyperparathyroidism-jaw tumor syndrome) or non-syndromic (familial isolated PHPT). There are limited data on the probability of testing positive for genetic mutation based on clinical presentation. The aim of this study was to determine potential associations between clinical and biochemical features and mutation in susceptibility genes for PHPT in patients with a family history of PHPT.
A retrospective analysis of 657 patients who had an initial parathyroidectomy for PHPT at a tertiary referral center. Logistic regression analyses were performed in 205 patients with a family history of PHPT to identify factors associated with a positive genetic test.
Of 657 patients, 205 (31.2%) had a family history of PHPT. Of those 205 patients, 123 (60%) had a germline mutation detected (91 MEN1, 14 CDC73, and 18 GCM2). In univariate analysis, younger age (45 years and younger), male sex, multigland disease, and parathyroid carcinoma were associated with positive germline mutation; biochemical cure after an initial parathyroidectomy was less frequent in patients with familial PHPT (96.2% vs 89.2%; p = 0.005). In multivariable analysis, age 45 years and younger, male sex, and multigland disease were independent factors associated with positive genetic testing.
In addition to a family history of PHPT, male sex, age 45 years and younger, and presence of multigland disease, should prompt physicians to offer the opportunity for genetic counseling and testing, as it could influence the management of patients with PHPT.
约 10%的原发性甲状旁腺功能亢进症 (PHPT) 患者存在遗传性疾病。遗传性 PHPT 可能是综合征性的(MEN1、2 和 4 以及甲状旁腺功能亢进-颌骨肿瘤综合征)或非综合征性的(家族性孤立性 PHPT)。基于临床表现,检测到基因突变阳性的概率数据有限。本研究旨在确定有 PHPT 家族史的患者中临床和生化特征与 PHPT 易感性基因突变之间的潜在关联。
对在三级转诊中心接受初始甲状旁腺切除术治疗 PHPT 的 657 例患者进行回顾性分析。对 205 例有 PHPT 家族史的患者进行 logistic 回归分析,以确定与阳性基因检测相关的因素。
在 657 例患者中,205 例(31.2%)有 PHPT 家族史。在这 205 例患者中,检测到 123 例(91 例 MEN1、14 例 CDC73 和 18 例 GCM2)种系突变。在单因素分析中,年龄(45 岁及以下)、男性、多发病灶和甲状旁腺癌与阳性种系突变相关;初始甲状旁腺切除术的生化缓解率在有家族性 PHPT 的患者中较低(96.2% vs 89.2%;p=0.005)。多因素分析中,年龄 45 岁及以下、男性和多发病灶是与阳性基因检测相关的独立因素。
除 PHPT 家族史外,男性、年龄 45 岁及以下以及多发病灶也应促使医生提供遗传咨询和检测的机会,因为这可能会影响 PHPT 患者的管理。